Hyponatremia in patients with esophageal cancer treated with chemotherapy including cisplatin

Ayako Shimada, Hiroya Takeuchi, Kazumasa Fukuda, Koichi Suda, Rieko Nakamura, Norihito Wada, Hirofumi Kawakubo, Yuukou Kitagawa

Research output: Contribution to journalArticle

Abstract

Background: Little is known about hyponatremia in patients with esophageal cancer treated with cisplatin-based chemotherapy. The aim of this study was to analyze the risk factors for hyponatremia and its effect on outcomes in patients with esophageal cancer treated with chemotherapy including cisplatin. Methods: We retrospectively analyzed the records of 137 patients with esophageal cancer who received chemotherapy including cisplatin for the first time between January 2011 and December 2014. Results: Hyponatremia (Na < 135 mEq/L) was seen in 77 patients (59%), of whom 29 had Grade 3 (120 ≤ Na < 130 mEq/L) or Grade 4 (Na < 120 mEq/L) hyponatremia. We divided patients into the hyponatremia group (patients with Na < 130 mEq/L) and the control group (patients with Na ≥ 130 mEq/L), and compared the results between the two groups. Three patients (2%) were diagnosed with the syndrome of inappropriate secretion of antidiuretic hormone. The serum sodium level before starting chemotherapy was significantly lower and white blood cell count was significantly higher in the hyponatremia group. Appetite loss was seen significantly more often in the hyponatremia group as the chemotherapy-related adverse effect. There was no significant difference in overall survival between the two groups. Conclusions: Hyponatremia is a common adverse effect induced by cisplatin. Caution should be exercised with patients with a low sodium level before starting chemotherapy. Hyponatremia can be associated with other chemotherapy-related adverse effects, and it should therefore be treated correctly.

Original languageEnglish
Pages (from-to)1-8
Number of pages8
JournalEsophagus
DOIs
Publication statusAccepted/In press - 2018 Apr 27

Fingerprint

Hyponatremia
Esophageal Neoplasms
Cisplatin
Drug Therapy
Sodium
Inappropriate ADH Syndrome
Appetite
Leukocyte Count
Control Groups
Survival

Keywords

  • Chemotherapy
  • Cisplatin
  • Esophageal cancer
  • Hyponatremina

ASJC Scopus subject areas

  • Gastroenterology

Cite this

Hyponatremia in patients with esophageal cancer treated with chemotherapy including cisplatin. / Shimada, Ayako; Takeuchi, Hiroya; Fukuda, Kazumasa; Suda, Koichi; Nakamura, Rieko; Wada, Norihito; Kawakubo, Hirofumi; Kitagawa, Yuukou.

In: Esophagus, 27.04.2018, p. 1-8.

Research output: Contribution to journalArticle

@article{e9e4b26687444630a689ffa911099469,
title = "Hyponatremia in patients with esophageal cancer treated with chemotherapy including cisplatin",
abstract = "Background: Little is known about hyponatremia in patients with esophageal cancer treated with cisplatin-based chemotherapy. The aim of this study was to analyze the risk factors for hyponatremia and its effect on outcomes in patients with esophageal cancer treated with chemotherapy including cisplatin. Methods: We retrospectively analyzed the records of 137 patients with esophageal cancer who received chemotherapy including cisplatin for the first time between January 2011 and December 2014. Results: Hyponatremia (Na < 135 mEq/L) was seen in 77 patients (59{\%}), of whom 29 had Grade 3 (120 ≤ Na < 130 mEq/L) or Grade 4 (Na < 120 mEq/L) hyponatremia. We divided patients into the hyponatremia group (patients with Na < 130 mEq/L) and the control group (patients with Na ≥ 130 mEq/L), and compared the results between the two groups. Three patients (2{\%}) were diagnosed with the syndrome of inappropriate secretion of antidiuretic hormone. The serum sodium level before starting chemotherapy was significantly lower and white blood cell count was significantly higher in the hyponatremia group. Appetite loss was seen significantly more often in the hyponatremia group as the chemotherapy-related adverse effect. There was no significant difference in overall survival between the two groups. Conclusions: Hyponatremia is a common adverse effect induced by cisplatin. Caution should be exercised with patients with a low sodium level before starting chemotherapy. Hyponatremia can be associated with other chemotherapy-related adverse effects, and it should therefore be treated correctly.",
keywords = "Chemotherapy, Cisplatin, Esophageal cancer, Hyponatremina",
author = "Ayako Shimada and Hiroya Takeuchi and Kazumasa Fukuda and Koichi Suda and Rieko Nakamura and Norihito Wada and Hirofumi Kawakubo and Yuukou Kitagawa",
year = "2018",
month = "4",
day = "27",
doi = "10.1007/s10388-018-0615-y",
language = "English",
pages = "1--8",
journal = "Esophagus",
issn = "1612-9059",
publisher = "Springer Japan",

}

TY - JOUR

T1 - Hyponatremia in patients with esophageal cancer treated with chemotherapy including cisplatin

AU - Shimada, Ayako

AU - Takeuchi, Hiroya

AU - Fukuda, Kazumasa

AU - Suda, Koichi

AU - Nakamura, Rieko

AU - Wada, Norihito

AU - Kawakubo, Hirofumi

AU - Kitagawa, Yuukou

PY - 2018/4/27

Y1 - 2018/4/27

N2 - Background: Little is known about hyponatremia in patients with esophageal cancer treated with cisplatin-based chemotherapy. The aim of this study was to analyze the risk factors for hyponatremia and its effect on outcomes in patients with esophageal cancer treated with chemotherapy including cisplatin. Methods: We retrospectively analyzed the records of 137 patients with esophageal cancer who received chemotherapy including cisplatin for the first time between January 2011 and December 2014. Results: Hyponatremia (Na < 135 mEq/L) was seen in 77 patients (59%), of whom 29 had Grade 3 (120 ≤ Na < 130 mEq/L) or Grade 4 (Na < 120 mEq/L) hyponatremia. We divided patients into the hyponatremia group (patients with Na < 130 mEq/L) and the control group (patients with Na ≥ 130 mEq/L), and compared the results between the two groups. Three patients (2%) were diagnosed with the syndrome of inappropriate secretion of antidiuretic hormone. The serum sodium level before starting chemotherapy was significantly lower and white blood cell count was significantly higher in the hyponatremia group. Appetite loss was seen significantly more often in the hyponatremia group as the chemotherapy-related adverse effect. There was no significant difference in overall survival between the two groups. Conclusions: Hyponatremia is a common adverse effect induced by cisplatin. Caution should be exercised with patients with a low sodium level before starting chemotherapy. Hyponatremia can be associated with other chemotherapy-related adverse effects, and it should therefore be treated correctly.

AB - Background: Little is known about hyponatremia in patients with esophageal cancer treated with cisplatin-based chemotherapy. The aim of this study was to analyze the risk factors for hyponatremia and its effect on outcomes in patients with esophageal cancer treated with chemotherapy including cisplatin. Methods: We retrospectively analyzed the records of 137 patients with esophageal cancer who received chemotherapy including cisplatin for the first time between January 2011 and December 2014. Results: Hyponatremia (Na < 135 mEq/L) was seen in 77 patients (59%), of whom 29 had Grade 3 (120 ≤ Na < 130 mEq/L) or Grade 4 (Na < 120 mEq/L) hyponatremia. We divided patients into the hyponatremia group (patients with Na < 130 mEq/L) and the control group (patients with Na ≥ 130 mEq/L), and compared the results between the two groups. Three patients (2%) were diagnosed with the syndrome of inappropriate secretion of antidiuretic hormone. The serum sodium level before starting chemotherapy was significantly lower and white blood cell count was significantly higher in the hyponatremia group. Appetite loss was seen significantly more often in the hyponatremia group as the chemotherapy-related adverse effect. There was no significant difference in overall survival between the two groups. Conclusions: Hyponatremia is a common adverse effect induced by cisplatin. Caution should be exercised with patients with a low sodium level before starting chemotherapy. Hyponatremia can be associated with other chemotherapy-related adverse effects, and it should therefore be treated correctly.

KW - Chemotherapy

KW - Cisplatin

KW - Esophageal cancer

KW - Hyponatremina

UR - http://www.scopus.com/inward/record.url?scp=85046006917&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85046006917&partnerID=8YFLogxK

U2 - 10.1007/s10388-018-0615-y

DO - 10.1007/s10388-018-0615-y

M3 - Article

C2 - 30225740

AN - SCOPUS:85046006917

SP - 1

EP - 8

JO - Esophagus

JF - Esophagus

SN - 1612-9059

ER -